Advate (octocog alfa) for hemophilia
Advate (antihemophilic factor, octocog alfa) is a recombinant (lab-made) clotting factor VIII (FVIII) concentrate used to prevent and control bleeding in children and adults with hemophilia A.
Search results for:
My struggle to find a suitable knee brace with hemophilia and EDS
About a month ago, my world was turned upside down when my kneecap dislocated while I was simply shifting my leg on a recliner. This unexpected incident brought back memories of my teenage years, when I underwent two surgeries to keep my kneecap in place. To add complexity to…
Depression, anxiety prevalent among hemophilia patients: Study
About a quarter (24.4%) of men with hemophilia A and B seen at a clinic in Turkey met the clinical threshold for depression, and nearly three-quarters (74.4%) had anxiety, according to a recent analysis. Having a high school degree was linked to the presence of depression, whereas having…
Roctavian (valoctocogene roxaparvovec-rvox) for hemophilia
Roctavian (valoctocogene roxaparvovec-rvox) is an approved one-time gene therapy that’s intended to reduce the risk of bleeds in certain adults with severe hemophilia A.
Social maladjustment is an unspoken issue in the hemophilia community
As a “HemoWife,” I’ve had the privilege of connecting with numerous people in the hemophilia community. While our shared experiences allow us to create a strong bond, one important topic often remains unspoken: the social and mental maladjustment that some people with hemophilia may face due to…
First hemophilia A patient in Europe treated with commercial Roctavian
A person in Germany with severe hemophilia A has been treated with Roctavian (valoctocogene roxaparvovec-rvox), the first time the gene therapy has been used commercially in Europe, according to BioMarin Pharmaceutical, its developer. “Today represents an important milestone for the hemophilia community and for patients and…
Ixinity safely controls bleeds in young children with hemophilia B
Treatment with Ixinity (trenonacog alfa) can safely control bleeds in children younger than 12 with severe or moderately severe hemophilia B. That’s according to data from a Phase 3/4 clinical trial that Medexus Pharmaceuticals, the company that markets Ixinity, presented at the National Hemophilia Foundation’s recent Bleeding…
How hemophilia reshaped my husband’s definition of masculinity
In a society deeply rooted in patriarchal values, expectations regarding masculinity often dictate men’s roles and behaviors. With its historical background of colonization, the Philippines, where I live, has fostered a set of traditional norms regarding how men must assert dominance, provide for their families, and adhere to…
FEIBA found to be safe, effective in severe hemophilia with inhibitors
When given as a prophylactic, or preventive therapy, or on an on-demand basis, FEIBA (factor eight inhibitor bypassing activity) was deemed safe and effective at lessening the number of bleeds in people with severe hemophilia and high levels of inhibitors. That’s according to four-year data from a real-world…
A letter to my younger self, who faced a new world of hemophilia
Dear 11-year-old me, Life might feel overwhelming at this moment, but remember, you are stronger than you realize. The road ahead will present challenges, but they will shape you into an incredibly resilient person. Your journey with your period has begun, and I know it’s tough. Those…